Quantum R&D Presentation September 2024

Quantum presents its diversified R&D portfolio spanning recreational and medical alcohol misuse treatments (unbuzzd, rekvry) and a proprietary multiple sclerosis therapeutic candidate (LUCID-21-302). The company maintains a capital-efficient model through royalty agreements and equity stakes while retaining exclusive IP rights for pharmaceutical applications and demyelinating disease treatments.